Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced participation in the AACR Virtual Annual Meeting II on June 22-24, 2020, with two studies on innate cell engagers from its ROCK® platform. Researchers from Affimed will present data on AFM24, a bispecific EGFR/CD16A Innate Cell Engager, and RO7297089, an anti-BCMA/CD16a antibody for multiple myeloma. A live teleconference will be held on May 15, 2020, at 8 am Eastern to discuss the abstracts and updates. Affimed continues to advance its clinical programs targeting cancer treatment.

Positive

• Participation in AACR Virtual Annual Meeting II highlights ongoing research and collaboration.
• Two studies showcasing innovative therapies could enhance market interest.

Negative

• None.

• Affimed researchers served as co-authors on an abstract for RO7297089 with scientific collaborators from Genentech, a member of the Roche Group
• Affimed will host a live teleconference at 8am Eastern to discuss the abstracts and recent corporate developments

Heidelberg, Germany, May 15, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK^® platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held on June 22-24, 2020. Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:

Title: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies

Abstract: 5659

Authors: Uwe Reusch, Michael Damrat, Susanne Wingert, Stefan H.J. Knackmuss, Thomas Mueller, Ivica Fucek, Ute Schniegler-Mattox, Kristina Ellwanger, Torsten Haneke, Andras Strassz, Wolfgang Fischer, Erich Rajkovic, Michael Tesar. Affimed GmbH, Heidelberg, Germany

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

Title: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma

Abstract:  6987

Authors: Satoko Kakiuchi-Kiyota, Melissa Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Luna Liu, Sivan Cohen, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida-Nagata, Shelly Zhong, Michael Dillon, Christoph Spiess, Steve Leong, Bing Zheng. Genentech Inc.; Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Thorsten Ross. Affimed; Andy Polson, Ayse Meric Ovacik. Genentech Inc.

Poster Release: The e-poster website will be launched on June 22, 2020. All e-posters will be available for browsing on this date.

More details about the programs for the AACR Virtual Annual Meeting II are available online at www.aacr.org.

Conference Call Information

Affimed will host a live teleconference today, Friday May 15^th at 8am Eastern to discuss the abstracts and recent corporate developments. The teleconference details will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts_cp/, and a replay of the teleconference will be accessible at the same link for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK^® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company’s initial clinical program, AFM13 for CD30-positive lymphomas, is currently enrolling patients for a registration-directed study in relapsed/refractory peripheral T cell lymphoma.  For more information, please visit www.affimed.com.   

Investor Contact

Solebury Trout, Thomas Hoffmann
Phone: 646-378-2931
Email: thoffmann@troutgroup.com or IR@affimed.com

FAQ

What are the key abstracts presented by Affimed at the AACR Virtual Annual Meeting II?

Affimed is presenting data on AFM24 and RO7297089, focusing on innovative cancer therapies.

When is Affimed's teleconference to discuss recent developments?

Affimed will host a live teleconference on May 15, 2020, at 8 am Eastern.

What is the significance of the ROCK® platform for Affimed?

The ROCK® platform is designed for developing specific therapies targeting various cancer types.

What is the focus of the research presented by Affimed in collaboration with Genentech?

The research focuses on bispecific antibodies for treating EGFR-positive malignancies and multiple myeloma.